Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Regeneron: PCSK9s Drowning In Paperwork

Executive Summary

A common problem is plaguing both Regeneron Pharmaceuticals Inc. and Amgen Inc. – paperwork, specifically, the abundance of paperwork patients and physicians need to fill out to prescribe a PCSK9 inhibitor.


Related Content

Repatha Monthly Dose Approved With On-Body Pushtronex System
Cigna’s Bradbury Talks PCSK9 Contracts And Value Versus Volume
Amgen's Harper Says Repatha Is Priced Right
Amgen Earnings Beat Expectations; Company Pushing Payers On Repatha


Related Companies